Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
HDT Bio
company
About
HDT Bio is a developer of RNA vaccines and therapeutics based on LION formulation technology.
- Seattle,Washington,United States
- 11 - 50
- https://www.hdt.bio
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $49M
- Industries
- Biopharma,Biotechnology,Pharmaceutical
- Founded date
- Jan 1, 2018
- Number Of Employee
- 11 - 50
- Operating Status
- Active
- Legal Name
- HDT Bio Corp.
HDT Bio is a developer of RNA vaccines and therapeutics based on LION formulation technology. The company's technology platforms and products cover a wide range of immunotherapy modalities and mechanisms of action, including innate immunity activation, adaptive immune response amplification, and tumor-tight junction disruption. Its mission is to maintain the rapid and significant progress made in the fight against the world's deadliest infectious diseases by developing cutting-edge immunotherapy technologies in a cost-effective manner across leading markets as well as low or middle-income countries.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
5
$67.95M
HDT Bio has raised a total of
$67.95M
in funding over 2 rounds. Their latest funding was raised on
Nov 30, 2022 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 30, 2022 | Grant | $49M | 1 |
Medical CBRN Defense Consortium
|
— | Detail |
| Aug 8, 2022 | Grant | $1.80M | 1 |
|
— | Detail |
| May 17, 2021 | Grant | $2.90M | 1 |
National Institutes of Health
|
— | Detail |
| Oct 5, 2020 | Seed | $6M | 2 |
Zoic Capital
|
— | Detail |
| Sep 1, 2020 | Grant | $8.25M | 1 |
National Institute of Allergy and Infectious Diseases
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
5
6
HDT Bio is funded by 6 investors.
Medical CBRN Defense Consortium
and US Army
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Medical CBRN Defense Consortium
|
Yes | Grant |
|
|
Yes | Grant |
|
National Institutes of Health
|
Yes | Grant |
|
Zoic Capital
|
Yes | Seed |
|
National Institute of Allergy and Infectious Diseases
|
Yes | Grant |
|
|
— | Seed |
Employee Profiles
Number of Employee Profiles
4
HDT Bio has 4 current employee profiles, including
Executive Peter Berglund
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
